RE:Bird Fluskys1 wrote: Agree guys, there is something very big in the works. This weekend I read. Director of CDC said, "It's not a question of if, it's a question of when the bird flu panddemic will occur with significant mortality in humans". It's estimated at 25 to 50% of those infected. That is shocking.
Then I read National Microbiology Lab had directed Theralase to direct its's research away from Covid vaccine research to develope this technology for an Avian Flu vaccine.
Again, I agree. There is obviously something very big in the works. Grants, you name it, "the whole 9 yards". They have to get ready for this next pandemic.
Yep...that reported 50% mortality is shocking. Fortunately, it is reportedly not easily transmissible in humans....YET. But as previous outbreaks/pandemics have taught us, it can be only a matter of time before a viral mutation(s) causes it to spill over into humans.
Traditional/standard vaccine manufacturing can be a slow process, & in the process of inactivating the virus, you can lose viral antigenic properties & hence reduce the chances for obtaining a healthy immune response (immunogenicity). Newer methods of vaccine production are sorely needed, & an alternative to the new mRNA technology would be welcomed by many imo.
Let's hope TLD 1433 can provide..1) A more novel/sophisticated vaccine that can maintain more of the antigenic properties during inactivation, 2) & thereby produce a more robust immune response with the potential to produce better cross-protective immunity (immune response to one infection confers protection against another) & 3) A shorter/more efficient/less costly manufacturing process to allow for rapid production/ramp-up when needed.
JMO
From the June 4, 2024 news release: Kevin Coombs, Ph.D., Professor, Medical Microbiology, University of Manitoba stated, "My team and I were excited by the results we have obtained as we have worked with several anti-viral compounds over the years and have found that RuvidarTM is far more potent than any of the others we have worked with, in fact RuvidarTM is effective at concentrations approximately 100-fold lower than those we have previously tested. I believe RuvidarTMhas the potential to be effective as a broad-spectrum viral vaccine able to mitigate the biothreat of various emerging infectious disease pathogens. In our research, we found that nanomolar and micromolar concentrations of RuvidarTMwere all that was required in order to inactivate 90 to 99.9% of all seven viruses that we tested, including H1N1 influenza virus, coronavirus, Zika virus, poxvirus and herpes virus. In fact, RuvidarTM at 3 mM completely killed the herpes virus."